Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ziyue Kong

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Pharmacological Research|January 21, 2023
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axisTianyao Lei, Tianwei Xu, Niu Zhang, et al.
Pharmacological Research|September 17, 2023
Corrigendum to "Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis" [Pharmacol. Res. 188 (2023) 106668]Tianyao Lei, Tianwei Xu, Niu Zhang, et al.
National Science Review|June 26, 2026
Self-powered intelligence for personalized healthcareYeyun Cai, Ziyue Kong, Pengfei Jin, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Pharmacological Research|January 21, 2023
Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axisTianyao Lei, Tianwei Xu, Niu Zhang, et al.
Pharmacological Research|September 17, 2023
Corrigendum to "Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis" [Pharmacol. Res. 188 (2023) 106668]Tianyao Lei, Tianwei Xu, Niu Zhang, et al.
National Science Review|June 26, 2026
Self-powered intelligence for personalized healthcareYeyun Cai, Ziyue Kong, Pengfei Jin, et al.
Pageof 1